Next, we stratified the patients, according to their tumor pathological TNM stages and we found that the percentages of CD14+CD169+ circulating monocytes were significantly lower in the patients with early stage of CRC than those with advanced stage of CRC (11.81% vs. 15.91%, P = 00003, Fig 4A). Here, SIGLEC1 is linked to neoplasm.